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AbsTrACT
advances in technology have led to a massive 
expansion in the capacity for genomic analysis, with a 
commensurate fall in costs. the clinical indications for 
genomic testing have evolved markedly; the volume 
of clinical sequencing has increased dramatically; 
and the range of clinical professionals involved in the 
process has broadened. there is general acceptance 
that our early dichotomous paradigms of variants being 
pathogenic–high risk and benign–no risk are overly 
simplistic. there is increasing recognition that the clinical 
interpretation of genomic data requires significant 
expertise in disease–gene- variant associations specific to 
each disease area. inaccurate interpretation can lead to 
clinical mismanagement, inconsistent information within 
families and misdirection of resources. it is for this reason 
that ’national subspecialist multidisciplinary meetings’ 
(mDms) for genomic interpretation have been articulated 
as key for the new nHs Genomic medicine service, of 
which Cancer Variant interpretation Group UK (CanViG- 
UK) is an early exemplar. CanViG- UK was established 
in 2017 and now has >100 UK members, including at 
least one clinical diagnostic scientist and one clinical 
cancer geneticist from each of the 25 regional molecular 
genetics laboratories of the UK and ireland. through 
CanViG- UK, we have established national consensus 
around variant interpretation for cancer susceptibility 
genes via monthly national teleconferenced mDms and 
collaborative data sharing using a secure online portal. 
We describe here the activities of CanViG- UK, including 
exemplar outputs and feedback from the membership.
bACkground
Clinical utility of cancer susceptibility genes 
(Csgs)
Analysis of germline (constitutional) variants in 
CSGs constitutes approximately one- quarter of 
activity in NHS Molecular Diagnostic Laboratories 
in England.1 Following identification of a patho-
genic variant (PV) in a CSG, incidence of/mortality 
from future cancers may be mitigated via (1) risk- 
reducing surgery (eg, mastectomy, gastrectomy, 
salpingo- ophorectomy and colectomy); (2) chemo-
prevention; (3) intensive screening; and (4) lifestyle 
modification.2 Family members negative for the 
familial CSG- PV can be spared anxiety and unnec-
essary screening. Many CSGs are associated with 
a pattern of cancer risk that is late- onset, variably 
penetrant and of autosomal dominant inheritance. 
PV- positive family members identified via cascade 
screening are often distributed across disparate 
genomics services.
Erroneous interpretation of CSG variant patho-
genicity can therefore result in (1) discordant 
management within families, (2) serious clinical 
consequences for individuals and (3) misdirection 
at population level of resources for screening and 
prevention.3–5 Increasingly, CSG- PVs are used as 
predictive biomarkers to inform cancer therapy. 
For all these reasons, robust, rapid, accurate variant 
analysis and interpretation of disease risk are crit-
ical to effective delivery of germline cancer genetics 
and improving outcomes for patients.
Evolving landscape of variant interpretation in 
germline cancer genetics
In the late 1990s, within a few years of identification 
of the relevant genes, laboratory analysis of CSGs 
became available in the UK via family cancer clinics.2 
If the cancer phenotype ascribed to the gene matched 
that found in the proband/family under study, with 
little additional evidence, a rare variant would often 
be labelled as pathogenic and thus causative.6 Subse-
quent large- scale population sequencing studies have 
revealed the degree of innocuous variation present in 
the human genome (and indeed in disease- associated 
genes) and ‘downgrading’ of many erroneously 
labelled PVs has been required.7 An era of caution 
followed, with much greater recourse to labelling of 
variants as ‘variants of uncertain significance’ (VUS/
VOUS). However, lack of systems for sharing new 
evidence has meant that many families have spent 
years in limbo with their ‘VUS’, even when data had 
long been available by which classification of their 
variant could be downgraded or upgraded.
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box 1 CanVIg objectives
The purpose of Cancer Variant Interpretation Group UK 
(CanVIG- UK) is to advance outcomes for patients by improving 
the accuracy and consistency of interpretation of variants in 
Cancer Susceptibility genes across the UK clinical- laboratory 
community. We have six specific objectives:
1. Creation of a national multidisciplinary professional network 
and regular forum.
2. Training and education.
3. Detailed specification for germline cancer genetics of the UK- 
ACGS Best Practice Guidelines for Variant Interpretation.
4. Ratification of additional guidance in germline cancer 
genetics relevant to the UK clinical- laboratory community.
5. Development of an online platform to facilitate information 
sharing and variant interpretation within the UK clinical- 
laboratory community.
6. UK contribution to international variant interpretation 
endeavours. 
Sharing of clinical variant data was somewhat improved with 
the advent of locus- specific databases (LSDs), such as Breast 
Cancer Information Core and Leiden Open Variant Data-
bases.8–11 However, the curation of clinical and molecular data 
in LSDs often remains suboptimal, with (1) erroneous nomencla-
ture, (2) duplication of entries and (3) use of differing classifica-
tion systems resulting in contradictory assignations.12
Using Myriad Genetics data from ~70 000 genetic tests 
for hereditary breast and ovarian cancer, in 2007, Easton and 
colleagues published a landmark multifactorial analysis through 
which ‘odds of causality’ were mathematically generated for 
1433 variants using clinical, pedigree and allelic data.13 In 2008, 
International Agency for Research on Cancer (IARC) collabo-
rators published the first formal five point variant interpreta-
tion system for CSGs, which included numeric thresholds for 
the probability of pathogenicity.14 Expert cancer susceptibility 
consortia such as the Evidence- based Network for the Inter-
pretation of Germline Mutant Alleles (ENIGMA) and the 
International Society for Gastrointestinal Hereditary Tumours 
(InSIGHT) further evolved these multifactorial variant classifi-
cation systems to incorporate tumour phenotype and in silico 
predictions.15–17 However, ENIGMA/InSIGHT approaches 
require statistical genetic–epidemiological analyses of large 
curated data series and are not reproducible by an individual 
diagnostic laboratory seeking to classify in a clinically relevant 
timescale a newly identified variant.
In 2015, the American College of Medical Geneticists 
(ACMG) published a variant interpretation framework enabling 
the combination by a diagnostic laboratory of disparate evidence 
sources for a newly identified genomic variant.18 The ACMG 
framework has subsequently been further evolved under the 
auspices of ClinGen, including (1) specification for how it is 
applied to particular genes and/or diseases (including TP53, 
CDH1 and PTEN); (2) deeper specification of particular criteria 
(eg, functional assays); and (3) exposition of the underpinning 
Bayesian model.19–23
Coordinated national uk approaches in variant interpretation
In 2016, with endorsement from NHS England and Health 
Education England, it was agreed formally by the UK Asso-
ciation of Clinical Genomic Science (UK- ACGS) to adopt the 
ACMG variant interpretation framework.24 25 The UK- ACGS 
established national groups for rare disease, germline cancer 
genetics, cardiac disease and hypercholesterolaemia to develop 
and disseminate practice in the application of the ACMG variant 
interpretation framework.24 In parallel was recognition within 
the NHS Genomic Medicine Service of the need for national 
subspecialist genomics MDMs.26 27 In response to these dual 
recommendations, Cancer Variant Interpretation Group UK 
(CanVIG- UK) was initiated in 2017.
CAnCEr VArIAnT InTErprETATIon group uk
The purpose of CanVIG- UK is to advance outcomes for patients 
by improving the accuracy and consistency of interpretation of 
variants in CSGs across the UK clinical genetics and molecular 
diagnostic laboratory communities (hereafter termed the UK 
clinical- laboratory community). We aim to progress this goal by 
advancing six objectives (see box 1).
Creation of a national multidisciplinary professional network 
and regular forum
CanVIG- UK has grown to now include >100 members, incor-
porating clinical and laboratory representation from each of the 
25 Molecular Diagnostic Laboratories and Clinical Genetics 
Services of the UK (NHS) and Ireland (see collaborators). This 
group comprises roughly equal proportions of clinical scientists 
and clinical geneticists, with two- thirds working exclusively or 
predominantly in cancer genetics (figure 1):
 ► The monthly teleconferenced MDM provides a forum to 
which problematic variants/cases are submitted. The vari-
ants submitted to the monthly variant surgery are circulated 
1 week in advance. CanVIG- UK members are asked (1) to 
ascertain whether additional cases and/or laboratory data 
exist locally and (2) to undertake local, independent clas-
sification of the variant. The relevant clinical and labora-
tory data are presented by the nominating laboratory. This 
is followed by input of any additional information by the 
broader CanVIG- UK group and a discussion regarding the 
legitimacy of the ACMG criteria awarded. Following this 
discussion and an online postdiscussion poll, a consensus 
CanVIG classification is generated (see online supplementary 
table 1). A detailed date- stamped CanVIG variant summary 
sheet is generated (see online supplementary appendix 2), 
which is circulated by email, uploaded to the CanVar- UK 
portal and submitted to ClinVar.
 ► The CanVIG- UK network is active throughout the month 
via the email forum, through which urgent queries can be 
debated and addressed.
Training and education
The discussion of cases at the MDM also provides valuable 
education for the clinical- laboratory community regarding appli-
cation of the ACMG framework and the vagaries of the evidence 
sources used (see figure 2). Additionally, through CanVIG- UK, 
we have supported training of the broader UK genetics and 
oncology communities in variant interpretation for CSGs.
detailed specification for germline cancer genetics of the uk-
ACgs best practice guidelines for Variant Interpretation
On behalf of the UK- ACGS, the rare disease variant interpreta-
tion group has generated and updates annually a highly detailed 
specification of the ACMG variant interpretation framework .24 
In cancer susceptibility, we typically observe variants relating 
to late- onset, common phenotypes. De novo and biallelic 
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Figure 1 overview of the CanViG- UK membership profile (survey of 
CanViG- UK members, performed on 29 october 2019, return rate 83/103 
(81%). HBoC, hereditary breast and ovarian cancer; mmR, mismatch repair. 
CanViG- UK, Cancer Variant interpretation Group UK.
paradigms are infrequent. We are typically much more reliant 
on variant frequency from case series and functional assays. 
Thus, an important remit for CanVIG- UK has been to develop 
a detailed specification of the UK- ACGS framework for these 
types of evidence to be used for CSG variant interpretation (see 
online supplementary appendix 1).
ratification of additional guidance in germline cancer 
genetics relevant to the uk clinical-laboratory community
Historically, the first presentation to the family cancer clinic was 
typically an unaffected individual, concerned by a significant 
family history. Increasingly, genetic analysis is now performed 
as part of routine work- up at cancer diagnosis, either through 
analysis of a germline sample or through therapeutically moti-
vated molecular analysis of the tumour. In both contexts, (1) 
focused testing of one or two genes has often been superseded 
by broad ‘cancer panels’ containing dozens or hundreds of 
genes; (2) patients may be unselected for family history; and (3) 
analysis and reporting in a tight time frame is typically required. 
A number of challenging issues have emerged, including
1. Categorisation and management of reduced penetrance vari-
ants in high- penetrance genes.
2. Variant interpretation and clinical management for moderate- 
penetrance genes.
3. Adaptation of variant interpretation and risk for different 
contexts of ascertainment.
4. Inference of germline findings from tumour- only sequencing.
While germane across genomics, consideration of these issues 
has become pressing within germline cancer genetics. Benefitting 
from its regular forum, multidisciplinary membership and align-
ment with both UK- ACGS and the UK Cancer Genetics Group 
(UK- CGG), we have used the CanVIG–UK monthly forum to 
evolve UK national multidisciplinary approaches on such issues 
(see online supplementary appendix 3).
development of an online platform to facilitate information 
sharing and variant interpretation within the uk clinical-
laboratory community
In germline cancer genetics, enrichment in cases (especially 
‘strong families’) is one of the most valuable clinical observa-
tions indicating variant pathogenicity. However, to date, we 
have struggled to quantify such observations on account of (1) 
failure to aggregate national data from distributed laboratories 
and (2) lack of a robust denominator.
In a collaborative venture between Public Health England 
(PHE) and the national network of molecular diagnostic labora-
tories, data from molecular testing of CSGs have been submitted 
via a pseudonymisation portal to the secure National Cancer 
Registration and Analysis Service (NCRAS) data environment of 
PHE.28 The national variant totals (numerator and denominator) 
are then shared by CanVIG- UK with the UK clinical- laboratory 
community via our online data system CanVar- UK (http://www. 
canvaruk. org/).
CanVar- UK provides additional annotations for 1 008 643 
variants from 95 CSGs. It includes variant- level annotations 
from LSDs (case counts), functional assays, splicing assays and 
multifactorial analyses for selected genes. Accessible only to 
registered CanVIG- UK clinical- laboratory users is a commu-
nity area for sharing non- identifiable variant- level data, such as 
local classifications, comments/notes, uploaded documents and 
results from local laboratory assays (eg, RNA analyses of poten-
tial splicing variants).
uk contribution to international variant interpretation 
endeavours
CanVIG- UK is an effective conduit between the UK clinical- 
laboratory germline cancer genetics community and relevant 
international variant interpretation endeavours in several 
regards:
 ► First, there is representation at the international ClinGen 
SVI group from the leadership of the UK- ACGS rare disease 
variant interpretation group. The regular crosstalk between 
leadership of the UK groups enables appraisal of the 
ClinGen SVI group of emerging analyses and activity within 
CanVIG- UK and the UK clinical- laboratory cancer genetics 
community.
 ► Second, multiple members of CanVIG- UK are members of 
gene- specific international endeavours such as ENIGMA, 
InSIGHT and ClinGen expert groups.
 ► Third, data generated by CanVIG- UK data have contrib-
uted to collaborative international consortia analyses, for 
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Figure 2 Perceived utility of CanViG- UK activities regarding local practice in CsG variant interpretation of seven activities (5: very useful to 1: not useful; 
survey of CanViG- UK members, performed on 29 october 2019, return rate 83/103 (81%)). aCGs, association of Clinical Genomic science; aCmG, american 
College of medical Geneticists; CanViG- UK, Cancer Variant interpretation Group UK; CsG, cancer susceptibility gene.
example, provision to ENIGMA of the summary PHE UK 
laboratory data on BRCA1/BRCA2 variants.
 ► Fourth, CanVIG- UK consensus classifications (and under-
pinning evidence) are shared via ClinVar. CanVIG- UK is the 
first UK organisation to submit clinical- laboratory variant 
classifications to ClinVar.
sustainability
Maintenance of a national multidisciplinary network, coordina-
tion of a regular teleconferenced MDMs and development of a 
data system is only feasible via sustained support. The activities 
of CanVIG- UK are currently supported by a Cancer Research 
UK Catalyst Award (CanGene- CanVar, @CangeneCanvar, 
C61296/A27223).
ConClusIon
CanVIG- UK is a multidisciplinary group comprising >100 clin-
ical scientists and senior genetics clinicians working in germ-
line cancer genetics, with representation from across the 25 
NHS molecular diagnostic laboratories of the UK and Ireland. 
Through CanVIG- UK, the UK clinical- laboratory germline 
cancer genetics community have evolved:
1. An email forum for real- time consultation on problematic 
variants.
2. A monthly teleconferenced MDM for detailed review of 
challenging variants and cases.
3. A national programme of using secure submissions of fre-
quency data from PHE.
4. An online data system (CanVar- UK) for sharing variant- level 
data both publicly and within a secure community region.
5. Detailed, consensus UK guidance for the interpretation of 
variants in CSGs.
6. Fruitful interactions with international CSG variant interpre-
tation endeavours.
In summary, we propose CanVIG- UK as an exemplar National 
Subspecialty Multidisciplinary Genomics Network. In this era 
of rapid emergence of genomic knowledge, such networks are 
becoming increasingly important to optimise collaborative 
specialist case review, information sharing and education.
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CanVIG-UK Consensus Specification for variant interpretation in CSGs (v1.2 03/03/2020) 
 
Appendix 1: CanVIG-UK Consensus Specification for Cancer Susceptibility 
Genes of ACGS Best Practice Guidelines for Variant Classification (v1.2 03/03/20) 
 
Guidance notes: 
 For the following evidence items, CanVIG-UK have no additional specification for CSGs to add 
beyond that provided in ACGS Best Practice Guidelines for Variant Classification 20201: PVS1, 
PS1, PS2, PM4, PM5, PM6, PP1, BS4, BP3, BP7 (shaded white).   
 For the remaining evidence items, whilst remaining consistent with ACGS Best Practice Guidelines 
for Variant Classification 20201, there are more specific recommendations pertaining to CSGs 
contained within the CanVIG-UK Consensus Specification (shaded grey).  
 A number of disease-specific expert panels have been established by the USA ClinGen Sequence 
Variant Interpretation (SVI) Working Group, generating disease/gene specific variant interpretation 
guidelines.  Following evaluation within the CanVIG-UK group, in subsequent updates to the 
CanVIG-UK specification, we shall include specific recommendations regarding adoption and 
implementation of these disease/gene specific-guidance. 
 
PVS1  
 
Null variant (nonsense, frameshift, canonical ±1 or 2 splice sites, initiation codon, single or multi-exon 
deletion) in a gene where LOF is a known mechanism of disease 
See LOF decision tree and criteria (Tayoun et al 2018)2  
 
PS1  
 
Same amino acid change as a previously established pathogenic variant, regardless of nucleotide 
change 
Use at Strong for a missense variant under evaluation whereby there is a reference missense variant 
classified as (likely) pathogenic that results in the same amino acid change 
Use at Moderate for an initiation codon variant under evaluation whereby there is a reference variant 
in the initiation codon classified as (likely) pathogenic 
Use at Supporting for a donor/acceptor splice region variant under evaluation whereby there is a 
reference variant at the same base residue classified as (likely) pathogenic.  The variant under 
evaluation must be predicted on in silico tools to be equally or more deleterious than the reference 
variant 
 
PS2, PM6 
 
PS2: De novo (both maternity and paternity confirmed) in a patient with the disease and no family 
history 
PM6: Assumed de novo, but without confirmation of paternity and maternity 
See ClinGen Sequence Variant Interpretation Recommendation for de novo Criteria (PS2/PM6)3 
https://www.clinicalgenome.org/site/assets/files/3461/svi_proposal_for_de_novo_criteria_v1_0.pdf). 
 
PS3 
 
Well-established in vitro or in vivo functional studies supportive of a damaging effect on the gene or 
gene product 
For assays of protein function 
 Discrimination Controls Reproducibility 
Strong relative protein 
activity assay or 
functional impact 
<25% compared to 
level for wildtype 
≥10 ‘true positive’  
≥10‘true-negative’ 
≥2 laboratories OR results 
demonstrably  reproducible from a 
single laboratory Moderate ≥5 ‘true positive’  
≥5 ‘true-negative’ 
Supporting ≥2 ‘true positive’  
≥2 ‘true-negative’ 
single laboratory 
 
For assays of splicing function 
_SUP 
_STR  _VSTR _MOD 
_STR _MOD 
_SUP _ VSTR _STR _MOD 
_SUP _ VSTR _STR _MOD 
_SUP 
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Very strong 2 orthogonal assays: exhibiting abnormal transcripts; no evidence of leakiness 
(see notes 4,8) 
Strong 1 assay: exhibiting abnormal transcripts; no evidence of leakiness (see note 8) 
Moderate ≥1 assay: exhibiting abnormal transcripts;  evidence of leakiness (see note 8) 
Supporting ≥1 assay: exhibiting abnormal/alternative transcripts which have been reported 
as present in normal controls (implying naturally occurring isoforms) (see note 12) 
Do not 
apply 
≥1 assay: exhibiting abnormal/alternative transcripts with evidence of extreme 
leakiness (see note 8) 
Explanatory Notes (all functional assays): 
● This criterion is for variant-specific analyses. Where functional data provides support at the gene 
rather than variant level (e.g. biochemical analysis), this should typically be incorporated within 
the phenotypic specificity criterion PP4 
● To be adopted by CanVIG-UK, a published assay requires independent review by two CanVIG-
UK registered clinical laboratory scientists 
● Guidance for more quantitative evaluation of functional assays has recently been published by 
the Clinical Genome Resource Sequence Variant Interpretation Working Group (Brnich et al 
2020)4.  Evaluation of these approaches by CanVIG-UK is underway but additional training is 
required.  We anticipate adoption as best practice of these more quantitative approaches for 
review of functional assays and will use the pan-CanVIG network to collate ‘ratings’ per assay 
Explanatory Notes (assays of splicing function): 
1. Experimental data may include quantitative assays (e.g. realtime-PCR, Sanger sequencing with 
formal quantitation of peak height, tape-station quantification of PCR products, minigene assay, 
RNAseq using NGS) and semi/non-quantitative assays (e.g. visual evaluation of the relative peak 
height of Sanger sequencing, gel-based evaluation and visualisation of reverse transcriptase 
PCR (RT-PCR) products, or analysis for evidence of nonsense mediated decay (e.g. where a 
SNV in trans with the putative splicing variant appears homozygous on RNA sequencing despite 
being heterozygous on DNA sequencing, indicating the loss of expression of the transcript 
containing the putative splicing variant)) 
2. Laboratory methodology should be appropriately validated: primers must have been tested in ≥5 
independent normal control reactions, not necessarily run at the same time (i.e. primers could be 
validated using 5 normal controls across several runs or runs as a batch on a single run) 
3. Assays must be performed in a diagnostically ISO accredited laboratory or recognized research 
laboratory with which direct consultation can be undertaken. If evidence is derived from an 
alternative source (e.g. publication only), downgrade by one level of evidence. All assays 
should evidence appropriate validations and controls (see note 2). 
4. Combinations of assays deemed orthogonal include (a) two PCR-based assays using different 
primers (b) ≥2 different platforms e.g. RT-PCR and minigene 
5. To attain very strong/strong, the criteria by which the disease mechanism is interpreted as loss 
of function should be met (as per PVS1 recommendations, Tayoun et al (2018)2) 
6. The exon in question must be present in the biologically relevant transcript  
7. Splicing impact must fulfil one of the criteria below, otherwise downgrade by one level of 
evidence 
a) out of frame + predicted to undergo NMD + removal of >10% of the protein 
b) in-frame but removal of a critical hotspot (as listed in PM1) 
c) in-frame but removal of >10% of the protein  
8. Although there will inevitably be gene by gene and exon by exon variation regarding the lower 
limit of % normal transcripts ('leakiness') at which normal protein function is maintained, this 
information is not always known. In the absence of specific data for a given gene/exon, the 
following thresholds of ‘leakiness’ should be applied: 
● Evidence against leakiness: ratio for allele of >80:20 (abnormal: normal) ==overall ratio of 
>40:60 (abnormal: normal) 
● Evidence of some leakiness: ratio for allele of >20:80 (abnormal: normal) ==overall ratio of 
>10:90 (abnormal: normal) 
● Evidence of extreme leakiness: ratio for allele of <20:80 (abnormal: normal) ==overall ratio 
of < 10:90 (abnormal: normal). Typically, abnormal transcript will be visible on gel but present 
only at extremely low level or not visible by Sanger sequencing 
The accuracy of different assays in correctly quantifying ratios of different transcripts will vary and 
is often poorly quantified. As improved data on the precision of different assays emerges, these 
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in one unrelated affected individual, and has not been reported in gnomAD (in a matched ethnic 
group) 
 
PM1, PP2 
 
PM1: Located in a mutational hot spot and/or critical and well-established functional domain (e.g. 
active site of an enzyme) without benign variation 
PP2: Missense variant in a gene that has a low rate of benign missense variation and in which 
missense variants are a common mechanism of disease 
Use PM1 for missense variants arising in a CSG domain well characterised as a “hotspot” for 
pathogenic missense variants    
Use PM1 at Moderate  for a variant in a mutational hotspot at which there is no benign variation  
Use PM1 at Supporting for a variant in a mutational hotspot at which there is some benign variation 
Use PP2 at Supporting where there is overall constraint for missense variation at the level of the 
region/exon/gene (Z≥3.09) 
Explanatory Notes: 
 The majority of CSGs act by loss of function.  Hence, for many of these genes, the majority of 
established pathogenic variants are truncating (early linkage analyses, agnostic to mechanism, 
support this).  Examples: BRCA1, BRCA2, PALB2, RAD51C, RAD51D, MLH1, MSH2, MSH6, 
PMS2.  However, in these genes, there are typically specific domains in which missense variation 
at key residues can cause loss of function.  Where benign variation typically also occur in these 
regions, PM1_sup can be used.  e.g. residues listed in by ENIGMA within BRCA1 (BRCT and 
RING domains) and BRCA2 (DNA binding domain) (https://enigmaconsortium.org/wp-
content/uploads/2018/10/ENIGMA_Rules_2017-06-29-v2.5.1.pdf) 5 
 
PM2 
 
Absent from controls (or at extremely low frequency if recessive) in Exome Sequencing Project, 1000 
Genomes Project, or Exome Aggregation Consortium 
Use at Moderate: where 0 observations of the variant in control series >50,000 individuals  
Use at Supporting where 1 observation on the variant in control series >50,000 individuals 
Explanatory Notes: 
● Ensure that sequencing coverage is sufficient 
● Be cautious in using this criterion for small insertions/deletions, as sequencing 
approaches/analytical methodologies can result in wide variation in calling of these variant types 
in NGS/exome/genome data 
● If PS4 has been used for case control data 
o The same dataset cannot be re-used for PM2 
o An alternative dataset may be used for PM2 of >50,000 individuals of the same ethnicity 
as that applied for PS4 OR 
o An alternative dataset may be used for PM2 of >50,000 individuals of ethnicity(ies) 
different to those for PS4, e.g. If the gnomAD NFE has been used for PS4, the remainder 
of the GNOMAD populations may be used for PM2 (eg 76,853 individuals non NFE from 
gnomAD v2.1, if NFE used for PS4) 
● If PS4 case control data has NOT been used 
o A dataset >50,000 individuals of the same ethnicity as your reference case/family  must 
be used for PM2 
 
PM3 
 
For recessive disorders, detected in trans with a pathogenic variant 
Use where variant found in trans with a pathogenic variant and the patient-level clinical features 
match those anticipated for the gene in question 
Use at Strong where variant found in ≥2 unrelated cases, and the features are distinctive for that 
gene 
Use at Moderate where variant found in 1 case, and the features are distinctive for that gene 
Use at Supporting where variant found in 1 case, and the features are distinctive for a set of genes 
Explanatory Notes: 
_SUP _MOD 
_SUP _MOD _STR 
_SUP _MOD 
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● Comprehensive analysis should be undertaken for the gene to exclude an alternative second 
pathogenic variant (e.g. including MLPA) in that gene  
● Comprehensive analysis should be undertaken for all other genes for which the phenotypic 
features overlap 
● Requires testing of parents (or offspring) to confirm phase 
● Can use for homozygous variants but downgrade by one evidence level (as per ClinGen SVI 
points-based system)9  
 
PM4 
 
Protein length changes as a result of in-frame deletions/insertions in a non-repeat region or stop-loss 
variants 
Use at Moderate for 
 In-frame insertions/deletions for which PVS1 is not applicable (Tayoun et al 20182) 
Use at Supporting for 
 In-frame insertions/deletions of a single amino-acid 
 
PM5 
 
Novel missense change at an amino acid residue where a different missense change determined to 
be pathogenic has been seen before 
Use at Moderate if 
 Reference variant is classified as pathogenic [OR likely pathogenic and reported in >1 individual] 
Use at Supporting if 
 Reference variant is classified likely pathogenic and only reported in 1 individual 
PM6: see above (PS2) 
 
PP1 
 
Co-segregation with disease in multiple affected family members in a gene definitively known to 
cause the disease 
 See Jarvik and Browning (2016)10 
PP2: see above (PM1) 
 
PP3 
 
Multiple lines of computational evidence support a deleterious effect on the gene or gene product 
(conservation, evolutionary, splicing impact) 
● Protein impact: Using a predefined strategy of  
○ 3/3 tools (one tool may be marginally below threshold)  
■ SIFT (deleterious), Polyphen HumVar ≥ (probably damaging) plus: 
● Align GVGD (C45, C65), (for BRCA1, BRCA2) OR 
● MAPP (bad) (for MMR genes) OR 
● CADD ( >15) (for any other CSG) 
○ Or use Revel (>0.7) as a single score 
● Splicing impact:  
○ Intron-exon boundary: MaxEnt >15% difference AND SSFL >5% difference11 
○ Deep intronic: predicted creation of a novel splice site of any strength, absent in the normal 
sequence 
 
 
 
 
 
 
 
_SUP _MOD 
_SUP _MOD 
_SUP _STR _MOD 
_SUP 
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PP4 
 
Patient’s phenotype or family history is highly specific for a disease with a single genetic aetiology 
 
Level Points  Cellular/molecular phenotype  Example 
- 0.5 Moderately predictive for 
germline aberration of one of a 
small set of genes 
MSI (for mismatch repair deficiency) 
Sup 1 Highly predictive for germline 
aberration of one of a small set of 
genes 
Aberration on mitomycin-induced 
chromosomal breakage (for genes 
related to Fanconi Anaemia) 
Sup 1 Moderately predictive for 
germline aberration of the 
specific gene 
LOH at chromosomal locus of tumour-
suppressor gene 
Loss on immunohistochemistry of single 
protein eg MSH6, PMS2 
Mod 2 Highly predictive for germline 
aberration of the specific gene 
Depletion of BRCA2 in lymphocytes and 
aberration on mitomycin-induced 
chromosomal breakage (for BRCA2-
related Fanconi Anaemia) 
Loss on immunohistochemistry of paired  
mismatch repair proteins e.g. MSH2 and  
MSH6  
Loss of MLH1+PMS2 on 
immunohistochemistry and normal 
MLH1 promoter methylation (for MLH1-
related mismatch repair deficiency)  
Explanatory Notes: 
● For CSGs, PP4 is largely applied for a cellular/molecular phenotype that implicates a 
particular gene or gene-set 
● Comprehensive analysis of the gene and related genes should have been undertaken to 
exclude an alternative pathogenic variant (including MLPA) 
● Individuals/tumours included must have been demonstrated to carry the germline variant 
● Evidence can be summed across multiple cases:  
o Total points: Suporting:1; Moderate: 2; Strong: 4 
o Only one individual per family can contribute  
● Up to two independent tumour phenotype assays can be included per case (e.g. MSI AND 
LOH). Strongly correlated tumour phenotypes from the same case cannot both be included, 
e.g. MSI and IHC 
● For CSGs the high-level clinical phenotype is often too non-specific (e.g. breast and/or ovarian 
cancer). For a number of pleiomorphic rare tumour and/or syndromic presentations of cancer 
susceptibility, the specificity of high level clinical phenotype has been captured within PS4 
within the case counting guidance (e.g. ClinGen criteria for CDH1, PTEN, TP537 8 12). For 
other pleiomorphic rare tumour and/or syndromic presentations (e.g. MEN1, HLRCC), such 
specifications are awaited.  If molecular data have been used within PS4 as part of a case 
counting exercise, then PP4 should not be applied 
 
PP5 
 
Reputable source recently reports variant as pathogenic, but the evidence is not available to the 
laboratory to perform an independent evaluation 
● Any classification of LP/P after 2016 from  
o ≥2 accredited North American diagnostic laboratories OR 
o a single North American diagnostic laboratory where the utilised evidence is clearly 
cited 
o an approved ClinGen Expert Group (3 star on ClinVar), e.g. INSIGHT, ENIGMA 
● When a single laboratory has classified as LP/P with provision of insufficient detail, it is 
advised that the individual laboratory is contacted to procure directly the evidence used for 
classification 
_SUP _STR _MOD 
_SUP 
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Additional comments: 
● This is an exceptional application, as per UK-ACGS specification.  For widely tested cancer 
susceptibility genes, classifications by large laboratories may have been derived from their 
substantial series of case data not otherwise publicly available  
 
BA1/BS1 
 
Allele frequency is “too high” for disorder (ExAC or GnomAD) 
Use BA1 as Stand_Alone when allele frequency in a large dataset of heterogeneous outbred 
population (>10,000 individuals) is: >1% or >0.5% (BRCA1, BRCA2, MLH1, MSH2) 
Use BS1 as Strong when allele frequency in a heterogeneous outbred population is > value specified 
for specific gene by respective expert group 
Explanatory Notes: 
 Occasional pathogenic founder mutations occurring at an appreciable frequency in Western 
Europeans were identified in early characterisation of autosomal dominant CSGs (e.g. CHEK2 
1100delC at ~0.6%). However, large volumes of sequencing in Western Europeans have now 
been performed for routinely tested CSGs. The reduction of the threshold of BA1 from 5% to 1% 
for CSGs and to 0.5% for very well characterised CGSs is predicated on existence of sufficiently 
high volumes of sequencing data to preclude the existence of hitherto undescribed common 
founder mutations 
 
BS2/BP2 
 
BS2: Observation in controls inconsistent with disease penetrance. Observed in a healthy adult 
individual for a recessive (homozygous), dominant (heterozygous), or X-linked (hemizygous) 
disorder, with full penetrance expected at an early age 
BP2: Observed in trans with a pathogenic variant for a fully penetrant dominant gene/disorder or 
observed in cis with a pathogenic variant in any inheritance pattern 
Use BP2 or BS2 at Supporting where no further genotyping or clinical/cellular phenotyping is 
possible 
Use BS2 at Strong where  
● laboratory analysis has been repeated using an orthogonal approach (e.g. different primers) 
to confirm homozygosity for allele AND 
● patient is of age at which biallelic pathogenic variants would be anticipated to be penetrant 
for a distinctive phenotype AND 
● patient has been actively examined to exclude relevant phenotype AND/OR had analysis of 
cellular phenotype 
OR         the homozygote is observed in a specified control population in addition to a heterozygote 
frequency meeting BS1 
Use BP2 at Strong where  
● alleles have been confirmed as in trans AND 
● patient is of age at which biallelic pathogenic variants would be anticipated to be penetrant 
for a distinctive phenotype AND 
● patient has been actively examined to exclude relevant phenotype AND/OR had analysis of 
cellular phenotype 
Explanatory Notes: 
 BS2 should only be used in the recessive context and for observation of a homozygote 
 BP2 is used for where the variant is reported as a compound heterozygote in conjunction with 
a pathogenic variant in unaffected individual 
 For cancer susceptibility genes, BP2 and BS2 should only be used for those genes in which 
typical (non-hypomorphic) biallelic variants cause a recognised phenotype that is fully penetrant 
from infancy.  Such genes include BRCA2, PALB2, MLH1, MSH2, MSH6, PMS2 
 
 
 
 
 
 
_STR _SA 
_SUP _STR 
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BS3 
 
Well-established in vitro or in vivo functional studies show no damaging effect on protein function or 
splicing  
For assays of protein function 
 Discrimination Controls Reproducibility 
Strong relative protein activity 
assay or functional 
impact  
>25% compared to level 
for wildtype 
≥10 ‘true positive’  
≥10 ‘true-
negative’ 
≥2 laboratories OR 
Results demonstrated as reproducible 
in single laboratory 
Sup ≥2 ‘true positive’  
≥2 ‘true-negative’ 
single laboratory 
 
For assays of splicing function 
Strong 1 assay: with no evidence of abnormal 
transcripts (% normal transcript>90%) 
ISO accredited laboratory or recognized 
research laboratory with which direct 
consultation can be undertaken 
Sup 1 assay: with no evidence of abnormal 
transcripts (% normal transcript>90%) 
alternative source of evidence (e.g. 
publication) 
Explanatory Notes: 
● BS3 should only be applied for an assay of protein function whereby the assay has been validated 
for variants in the relevant domain to ensure that the mechanism of pathogenicity captured by the 
assay in question is relevant to that variant 
● BS3 should not be applied for an assay of protein function when in silico tools predict effect on 
splicing and/or for the first or last three bases of the exon 
● A splicing assay can only be used for BS3 for intronic variants and those in the first or last three 
bases of the exon 
● Evidence of amplification of both alleles is required (i.e. sequencing should demonstrate the SNV 
in question or another nearby SNV, on the background of the wildtype sequence). This is 
necessary to exclude generation of a ‘normal’ RNA result when the splicing aberration has not 
been detected by the assay used (e.g. due to intron retention, size too large for the PCR to 
amplify) 
● When BS3 is applied for splicing, BP4 (in silico evidence), cannot be applied.  For assays of 
protein function BS3 and BP4 can be combined. 
● For specification of acceptable assays and QC standards, see PS3 
 
BS4 
 
Non segregation with disease 
 See Jarvik and Browning (2016)10 
 For cancer susceptibility genes for which the phenotype is non-specific and/or feature age-
related/reduced penetrance, phenocopies or hypomorphic variants, expert review is 
recommended for application of  BS4 pertaining to non-segregation.  
 
BP1 
 
Missense variant in a gene for which primarily truncating variants are known to cause disease 
Use at Supporting for genes/gene regions in which >95% of reported pathogenic variants are 
truncating 
Explanatory note: 
o Can be used outside of BRCT and RING domains for BRCA1 and outside of DNA-binding domain 
for BRCA2. Other examples of genes for which criterion can be used include PALB2 and APC 
o Variant should be evaluated to exclude splicing impact 
o Should not be used if the specific amino acid residue is highly conserved in mammals 
BP2: see above (BS2) 
 
 
 
_SUP _STR 
_STR 
_SUP 
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BP3 
 
In-frame deletions in a repetitive region without a known function 
 Particularly relevant to poorly conserved regions 
 
BP4 
 
Multiple lines of computational evidence suggest no impact on gene or gene product (conservation, 
evolutionary, splicing impact, etc.) 
● Splicing impact:  
○ Intron-exon boundary: Minimal difference in readings for each of MaxEnt AND SSFL 
○ AND no evidence of prediction of exonic/deep intronic novel splice site of any strength 
AND 
● Protein impact: Using a predefined strategy of  
○ 3/3 tools (one tool may be marginally above threshold)  
■ SIFT (tolerated), Polyphen HumVar (benign) plus: 
● Align GVGD (C0, C15), (for BRCA1, BRCA2) 
● MAPP (good) (for MMR genes) 
● CADD (<10) (for any other CSG) 
○ Or Revel (<0.4) as a single score 
 
BP5 
 
Variant found in a case with an alternate molecular basis for disease  
This should not be applied for autosomal dominant incompletely penetrant non-syndromic genes 
associated with common cancers e.g. HBOC (hereditary breast and ovarian cancer) 
Explanatory note: 
● Co-occurrence of ≥2 pathogenic variants in different cancer susceptibility genes is widely 
reported. Typically, the phenotype exhibited is indistinguishable from that of a single pathogenic 
variant 
 
BP6 
 
Reputable source recently reports variant as benign, but the evidence is not available to the 
laboratory to perform an independent evaluation 
Explanatory Notes: 
● Any classification of LB/B after 2016 from  
o ≥2 accredited North American diagnostic laboratory OR 
o a single North American diagnostic laboratory where the utilised evidence is clearly 
listed 
o ClinGen Expert Group, e.g. INSIGHT, ENIGMA 
● When a single laboratory has classified as LB/B with provision of insufficient detail, it is 
advised that the individual laboratory is contacted to procure directly the evidence used for 
classification 
Additional comments: 
This is an exceptional application, as per UK-ACGS specification, as for commonly tested cancer 
susceptibility genes, classifications by large laboratories may have be derived from their substantial 
series of case data not otherwise publicly available 
 
BP7 
 
A synonymous (silent) variant for which splicing prediction algorithms predict no impact to the splice 
consensus sequence nor the creation of a new splice site AND the nucleotide is not highly conserved 
 Not to be used if any cause for suspicion of an impact on splicing 
 
References 
_SUP 
_SUP 
_SUP 
_SUP 
_SUP 
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Appendix 2: Example of CanVIG-UK classification summary report  
 
 
PATHOGENIC 
Criteria 
Weight (supporting, 
moderate, strong, very 
strong) 
BENIGN 
Criteria 
Weight (supporting, 
strong) 
PVS1(null)  BS1/BA1 (controls)  
PS4 (case control) Very strong BP4 (in silico)  
PM2 (absent control) Mod BP1 (only trunc)  
PP3 (in silico)  BP7 (synonymous)  
PM5 (same residue)  BP3 (in frame, no func)  
PM1 (hot spot)  BS3 (functional assay)  
PP1 (Segregation)  BS4 (non segregation)  
PS3 (functional assay) Strong BP2 (biallelic)  
PM3 (biallelic)  BP6 (other databases)  
PP5 (other databases) Sup Alternative cause (BP5)  
Specific phenotype (PP4)    
De novo (PM6, PS2)    
Total 1 very strong, 1 strong, 1 
mod, 1 sup 
Total  
Classification 5-Pathogenic 
 
Variant classification by Can-VIG UK (Cancer Variant Interpretation UK) 
Can-VIG UK is a working group convened on behalf of the UK ACGS (Association of Clinical Genetic Scientists), 
which includes registered clinical scientists and clinical geneticists representing the following UK Regional 
molecular diagnostic laboratories: Aberdeen, Belfast, Birmingham, Bristol, Cambridge, Cardiff, Dublin, Exeter, 
Glasgow, GOSH, Guy's, Leeds, Liverpool (Cheshire & Merseyside), Oxford, Manchester, Newcastle, Nottingham, 
Sheffield , SW Thames (St George's), Wessex (Salisbury/Southampton), University Hospitals of Leicester.  
Submitter Dr Clare Turnbull MD PhD FRCP FRCPath Date 15/11/19 
Gene BRCA1 Transcript NM_007294.3 
ENST00000357654 
LRG_292t1 
Variant   c.53T>C (p.Met18Thr) 
Population data The variant was observed in 7 independent UK families undergoing clinical diagnostic testing, 
the denominator of which dataset of clinical testing was 25,773. Case control comparison 
against ethnically matched population data (7/25,773 in familial cases against 0/64,603 
GNOMAD NFE controls pexact= 0.0015 
 
There are additional reports of this variant in ClinVar (6), BIC (3) LOVD3 (22), UMD(7), 
DMuDB(7) 
 
The variant is absent in the remainder of the GNOMAD populations (76,853 individuals) 
Prediction 
(based on 
variant 
type/location), 
IN silico tools 
AlignGVGD class: C45 
SIFT prediction: deleterious 
MAPP prediction: bad 
Polyphen2 HumVar prediction: benign 
CADD scaled score [0-99]: 16.18 
SuSPect score [0-100]: 95 
Functional data Findlay et al. 2018:  Non-functional via saturation editing analysis using haploid BRCA1 
construct 
Segregation 
data 
 
De novo data  
Allelic data 
(biallelic 
observations) 
 
Other 
classifications 
Ambry LP 2018, Gene Dx LP 2018, Counsyl LP 2018 Color LP 2018 
Enigma 2019 (multifactorial analysis): pathogenic 
Other  
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Appendix 3: CanVIG-UK Consensus Guidance for Variants of Reduced 
Penetrance in High Penetrance Cancer Susceptibility Genes 
 
● Variant interpretation and classification should be undertaken using the ACMG 
framework (with ACGS and CanVIG-UK specifications) 
● If any of the below criteria are met, the variant should be assigned the relevant ACMG 
class but with addendum of “reduced penetrance” 
● The report should reference and recommend the nationally ratified clinical management 
recommendations for that gene for variants of reduced penetrance 
● Clinical management recommendations for variants of reduced penetrance for each 
gene should be established by disease-specific experts 
Criterion 1: Down-modification of classic biallelic phenotype  
Abnormal physical AND cellular phenotype associated with biallelic mutations is present but notably 
milder 
Example: BRCA2-related Fanconi anaemia:  
● Cancer is not penetrant by 5 years AND 
● Congenital abnormalities and physical features are mild AND 
● Incomplete functional abrogation of chromosomal breakage following mitomycin C exposure 
OR BRCA2-specific assays show only modest depletion of BRCA2 in quantity and/or 
function 
Criterion 2: Well calibrated assay gives intermediate effect  
● Highly predictive and well-calibrated published functional assay demonstrate intermediate effect, 
ie significant impairment of protein function but not at level demonstrated for truncating mutations 
in gene (e.g. Guidugli et al for BRCA213 14, Findlay et al 2019 for BRCA115) 
Criterion 3: Segregation analysis gives lower estimate of penetrance 
● Formal genetic epidemiologic analyses demonstrate variant to be associated with disease but of 
penetrance statistically significantly reduced compared to established estimates eg: BRCA1 
c.5096G>A p.Arg1699Gln16 17 
 
12. ClinGen CDH1 Expert Panel Specifications to the ACMG/AMP Variant Interpretation 
Guidelines Version 2, 2019. 
13. Guidugli L, Carreira A, Caputo SM, Ehlen A, Galli A, Monteiro AN, Neuhausen SL, Hansen 
TV, Couch FJ, Vreeswijk MP. Functional assays for analysis of variants of uncertain 
significance in BRCA2. Human mutation 2014;35(2):151-64. doi: 10.1002/humu.22478 
[published Online First: 2013/12/11] 
14. Guidugli L, Shimelis H, Masica DL, Pankratz VS, Lipton GB, Singh N, Hu C, Monteiro ANA, 
Lindor NM, Goldgar DE, Karchin R, Iversen ES, Couch FJ. Assessment of the Clinical 
Relevance of BRCA2 Missense Variants by Functional and Computational 
Approaches. American journal of human genetics 2018;102(2):233-48. doi: 
10.1016/j.ajhg.2017.12.013 [published Online First: 2018/02/06] 
15. Findlay GM, Daza RM, Martin B, Zhang MD, Leith AP, Gasperini M, Janizek JD, Huang 
X, Starita LM, Shendure J. Accurate functional classification of thousands of 
<em>BRCA1</em> variants with saturation genome editing. bioRxiv 2018 
16. Spurdle AB, Whiley PJ, Thompson B, Feng B, Healey S, Brown MA, Pettigrew C, Van 
Asperen CJ, Ausems MG, Kattentidt-Mouravieva AA, van den Ouweland AM, 
Lindblom A, Pigg MH, Schmutzler RK, Engel C, Meindl A, Caputo S, Sinilnikova OM, 
Lidereau R, Couch FJ, Guidugli L, Hansen T, Thomassen M, Eccles DM, Tucker K, 
Benitez J, Domchek SM, Toland AE, Van Rensburg EJ, Wappenschmidt B, Borg A, 
Vreeswijk MP, Goldgar DE. BRCA1 R1699Q variant displaying ambiguous functional 
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Supplementary table 1: Variants reclassified to date in CanVIG-UK multidisciplinary 
meeting; RP: reduced penetrance 
 
 
Date of 
CanVIG-
UK 
review 
Gene Variant Previous UK 
clinical 
classifications: 
most common 
(others) 
CanVIG-UK 
consensus 
classification 
Submission 
to ClinVar 
Nov-17 BRCA1 c.53T>C p.Met18Thr 4 (3,5) 5 Y 
Dec-17 BRCA2 c.8063T>C p.Leu2688Pro 3 (4,5) 5 Y 
Jan-18 BRCA1 c.4096+3A>G 3 (2, 4) 2 Y 
Feb-18 BRCA1 c.442-22_442-13del 3 (4,5) 4 Y 
Mar-18 MLH1 c.122A>G p.Asp41Gly 3 (4,5) 5 Y 
April-18 TP53 c.998G>A p.Arg333His 3 (4) 3 Y 
Jun-18 BRCA2 c.9302T>G p.Leu3101Arg 4 (3,5) 5  Y 
Jul-18 BRCA1 c.4963T>C p.Ser1655Pro 4 (3,5) 5 Y 
Jul-18 BRCA1 c.4964C>T p.Ser1655Phe 4 (3,5) 5 Y 
Jul-18 BRCA1 c.5207T>C p.Val1736Ala 3 (4) 5 Y 
Aug-18 BRCA1 c.4357+6T>C 3 (4,5) 5 Y 
Aug-18 BRCA2 c.8378G>A p.Gly2793Glu 3 (4,5) 5  Y 
Sep-18 BRCA2 c.8524C>T p.Arg2842Cys 3 (4,5) 5 RP  Y 
Oct-18 MLH1 c.1676T>G p.Leu559Arg  3 (4,5) 4  Y 
Nov-18 MSH2 c.1807G>A p.Asp603Asn 4 (3,5) 4  Y 
Jan-19 MLH1 c.440G>T p.Gly147Val 3 (4) 3  Y 
Mar-19 MLH1  c.794G>A p.Arg265His 3 3  Y 
Apr-19 BRCA1 c.5357T>C p.Leu1786Pro 3 (4) 4  Y 
Apr-19 MLH1 c.1595G>A p.Gly532Asp 3 (4,5) 4  Y 
May-19 APC  c.2497A>C p.Ser833Arg 3 (2) 3  Y 
May-19 APC  c.6724A>G p.Ser2242Gly 3 (2) 2  Y 
May-19 BMPR1A c.1328G>A p.Arg443His 3 (4,5) 4  Y 
May-19 BRCA1 c.5153-26 A>G 3 (4,5) 3  Y 
May-19 BRCA2 c.520C>T p.Arg174Cys 3 (4) 3  Y 
Sep-19 TP53 c.799C>T p.Arg267Trp 3 (4,5) 4  Y 
Oct-19 TP53 c.1141A>G p.Lys381Glu 3 (4) 3  Y 
Oct-19 TP53 c.322G>C p.Gly108Arg 4 (3,5) 3  Y 
Oct-19 TP53 c.472 C>T p.Arg158Cys 3 3  Y 
Oct-19 TP53 c.794T>A p.Leu265Gln 3 (4,5) 4  Y 
Oct-19 TP53 c.560-14_560-13delCT 3 (4,5) 3  Y 
Jan-20 TP53 c.453-455delCCC p.Pro153del 3 (4,5) 3  Y 
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